← Back to headlines
Teva Reports Positive Mid-Stage Trial Results for Celiac Disease Drug
Teva Pharmaceuticals has announced that its experimental anti-IL-15 antibody therapy successfully met its primary endpoints in a mid-stage clinical trial for celiac disease. The positive results further validate the drug's potential as a pipeline-in-a-product candidate.
2 Sept, 11:03 — 2 Sept, 11:34
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (46/100)3 sources25/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center2
Center (2)
Reuterstaiwan-news
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 3 regions13/34
Intl1US1Taiwan1
Sources
Showing 2 of 3 sources
seeking-alphaMixed10h ago
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma
Read full article →taiwan-newsMostly Factual11h ago
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential - Taiwan News
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Taiwan News
Read full article →Coverage Timeline
First report: taiwan-news · 2 Sept, 11:03|Full coverage: 3 · 4h|Window: 4h
Left-leaningCenterRight-leaning
